Recently, the evidence of high antitumor activity as well as a safe and manageable toxicity profile of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, allowed this combination to become a new standard-of-care for BRAF V600-mutant NSCLC patients [3, 4]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.